VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q56481169 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000044.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q56481169‏
024 ‎‡a 0000-0001-7747-3349‏ ‎‡2 orcid‏
024 ‎‡a 7201855650‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q56481169‏
100 0 ‎‡a Guido Ferrari‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Guido Ferrari‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions‏
670 ‎‡a Author's A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies‏
670 ‎‡a Author's A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays‏
670 ‎‡a Author's A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects‏
670 ‎‡a Author's A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.‏
670 ‎‡a Author's A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques‏
670 ‎‡a Author's Absence of Immunodominant Anti-Gag p17 (SL9) Responses among Gag CTL-Positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele‏
670 ‎‡a Author's Acute HIV-1 infection in the Southeastern United States: a cohort study‏
670 ‎‡a Author's Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses‏
670 ‎‡a Author's Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition‏
670 ‎‡a Author's Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.‏
670 ‎‡a Author's Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge‏
670 ‎‡a Author's Aggregate complexes of HIV-1 induced by multimeric antibodies‏
670 ‎‡a Author's An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.‏
670 ‎‡a Author's An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum‏
670 ‎‡a Author's An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques‏
670 ‎‡a Author's Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial‏
670 ‎‡a Author's Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family‏
670 ‎‡a Author's Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia‏
670 ‎‡a Author's Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development‏
670 ‎‡a Author's Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation‏
670 ‎‡a Author's Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.‏
670 ‎‡a Author's Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1‏
670 ‎‡a Author's Automating Procedures for Processing, Cryopreservation, Storage, and Manipulation of Human Peripheral Blood Mononuclear Cells‏
670 ‎‡a Author's Beyond Viral Neutralization‏
670 ‎‡a Author's Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition‏
670 ‎‡a Author's Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.‏
670 ‎‡a Author's Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial‏
670 ‎‡a Author's CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection‏
670 ‎‡a Author's CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition‏
670 ‎‡a Author's CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.‏
670 ‎‡a Author's Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection‏
670 ‎‡a Author's Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques‏
670 ‎‡a Author's Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers‏
670 ‎‡a Author's Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk‏
670 ‎‡a Author's Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study‏
670 ‎‡a Author's Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.‏
670 ‎‡a Author's Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques‏
670 ‎‡a Author's Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies‏
670 ‎‡a Author's Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC" ‏
670 ‎‡a Author's Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy‏
670 ‎‡a Author's Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques‏
670 ‎‡a Author's Defining the risk of SARS-CoV-2 variants on immune protection‏
670 ‎‡a Author's Discriminating between latent and active tuberculosis with multiple biomarker responses.‏
670 ‎‡a Author's Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection‏
670 ‎‡a Author's Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects‏
670 ‎‡a Author's DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies‏
670 ‎‡a Author's Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells‏
670 ‎‡a Author's Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers‏
670 ‎‡a Author's Effect of Highly Active Antiretroviral Therapy and Thymic Transplantation on Immunoreconstitution in HIV Infection‏
670 ‎‡a Author's Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection‏
670 ‎‡a Author's Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.‏
670 ‎‡a Author's Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment‏
670 ‎‡a Author's Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection‏
670 ‎‡a Author's Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus‏
670 ‎‡a Author's Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses‏
670 ‎‡a Author's Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition‏
670 ‎‡a Author's Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials‏
670 ‎‡a Author's Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults‏
670 ‎‡a Author's FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial‏
670 ‎‡a Author's Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection‏
670 ‎‡a Author's Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.‏
670 ‎‡a Author's Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.‏
670 ‎‡a Author's Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates‏
670 ‎‡a Author's Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers‏
670 ‎‡a Author's High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers‏
670 ‎‡a Author's High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects‏
670 ‎‡a Author's High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses‏
670 ‎‡a Author's HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies‏
670 ‎‡a Author's HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine‏
670 ‎‡a Author's HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages‏
670 ‎‡a Author's HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis‏
670 ‎‡a Author's HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities‏
670 ‎‡a Author's HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies‏
670 ‎‡a Author's HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci‏
670 ‎‡a Author's HIV antibodies for treatment of HIV infection‏
670 ‎‡a Author's HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC‏
670 ‎‡a Author's HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies‏
670 ‎‡a Author's HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians‏
670 ‎‡a Author's HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition‏
670 ‎‡a Author's Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques‏
670 ‎‡a Author's Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection‏
670 ‎‡a Author's Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses‏
670 ‎‡a Author's IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).‏
670 ‎‡a Author's Immune-correlates analysis of an HIV-1 vaccine efficacy trial‏
670 ‎‡a Author's Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa‏
670 ‎‡a Author's Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques‏
670 ‎‡a Author's Immunodominance and Cross-Reactivity of B5703-Restricted CD8 T Lymphocytes from HIV Type 1 Subtype C-Infected Ethiopians‏
670 ‎‡a Author's Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults‏
670 ‎‡a Author's Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine‏
670 ‎‡a Author's Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.‏
670 ‎‡a Author's Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome‏
670 ‎‡a Author's Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge‏
670 ‎‡a Author's Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site‏
670 ‎‡a Author's Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization‏
670 ‎‡a Author's Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design‏
670 ‎‡a Author's Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses‏
670 ‎‡a Author's Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees‏
670 ‎‡a Author's Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication‏
670 ‎‡a Author's Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk‏
670 ‎‡a Author's Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity‏
670 ‎‡a Author's Intradermal HIV-1 DNA immunization using needle-free Zetajet<sup>TM</sup> injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.‏
670 ‎‡a Author's Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum‏
670 ‎‡a Author's Lack of infection in HIV-exposed individuals is associated with a strong CD8‏
670 ‎‡a Author's Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response‏
670 ‎‡a Author's Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs‏
670 ‎‡a Author's Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates‏
670 ‎‡a Author's Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4+/Viral Load Discordance‏
670 ‎‡a Author's Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection‏
670 ‎‡a Author's Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines‏
670 ‎‡a Author's Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation‏
670 ‎‡a Author's Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques.‏
670 ‎‡a Author's Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission‏
670 ‎‡a Author's Measurement of cytokine release at the single cell level using the ELISPOT assay‏
670 ‎‡a Author's Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk‏
670 ‎‡a Author's Naïve T Cells Are Maintained in the Periphery During the First3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function‏
670 ‎‡a Author's Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection‏
670 ‎‡a Author's Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination‏
670 ‎‡a Author's Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication.‏
670 ‎‡a Author's Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays‏
670 ‎‡a Author's P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants‏
670 ‎‡a Author's Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge‏
670 ‎‡a Author's Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells‏
670 ‎‡a Author's Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells‏
670 ‎‡a Author's Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial‏
670 ‎‡a Author's Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination‏
670 ‎‡a Author's Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults‏
670 ‎‡a Author's Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens‏
670 ‎‡a Author's Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine‏
670 ‎‡a Author's Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost‏
670 ‎‡a Author's Proceedings of the Frontiers of Retrovirology Conference 2016.‏
670 ‎‡a Author's Progress in HIV-1 vaccine development.‏
670 ‎‡a Author's Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control‏
670 ‎‡a Author's Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure‏
670 ‎‡a Author's Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection‏
670 ‎‡a Author's Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC‏
670 ‎‡a Author's Response to Comment on "CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection" ‏
670 ‎‡a Author's Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials‏
670 ‎‡a Author's Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial‏
670 ‎‡a Author's Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults‏
670 ‎‡a Author's Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.‏
670 ‎‡a Author's SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses‏
670 ‎‡a Author's Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses‏
670 ‎‡a Author's Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses‏
670 ‎‡a Author's Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection‏
670 ‎‡a Author's T Cell Assays and MIATA: The Essential Minimum for Maximum Impact‏
670 ‎‡a Author's Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques‏
670 ‎‡a Author's Teaching advanced flow cytometry in Africa: 10 years of lessons learned‏
670 ‎‡a Author's The Center for HIV/AIDS Vaccine Immunology‏
670 ‎‡a Author's The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells‏
670 ‎‡a Author's The External Quality Assurance Oversight Laboratory‏
670 ‎‡a Author's The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay‏
670 ‎‡a Author's The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection‏
670 ‎‡a Author's The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells‏
670 ‎‡a Author's The human antibody response to the surface of Mycobacterium tuberculosis‏
670 ‎‡a Author's Thinking outside the gate: single-cell assessments in multiple dimensions‏
670 ‎‡a Author's Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers‏
670 ‎‡a Author's Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques‏
670 ‎‡a Author's Toll-like receptor 7/8‏
670 ‎‡a Author's Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques‏
670 ‎‡a Author's Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition‏
670 ‎‡a Author's V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity‏
670 ‎‡a Author's Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination‏
670 ‎‡a Author's Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide‏
670 ‎‡a Author's Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.‏
670 ‎‡a Author's Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2‏
670 ‎‡a Author's Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys‏
670 ‎‡a Author's Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies‏
670 ‎‡a Author's Vertical T cell immunodominance and epitope entropy determine HIV-1 escape‏
909 ‎‡a (scopus) 7201855650‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000177473349‏ ‎‡9 1‏
912 ‎‡a proceedingsofthefrontiersofretrovirologyconference‏ ‎‡A Proceedings of the Frontiers of Retrovirology Conference 2016.‏ ‎‡9 1‏
912 ‎‡a definingtheriskofsarscov2variantsonimmuneprotection‏ ‎‡A Defining the risk of SARS-CoV-2 variants on immune protection‏ ‎‡9 1‏
919 ‎‡a verticaltcellimmunodominanceandepitopeentropydeterminehiv1escape‏ ‎‡A Vertical T cell immunodominance and epitope entropy determine HIV-1 escape‏ ‎‡9 1‏
919 ‎‡a variabilityoftheifnγelispotassayinthecontextofproficiencytestingandbridgingstudies‏ ‎‡A Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies‏ ‎‡9 1‏
919 ‎‡a vaccineprotectionagainstacquisitionofneutralizationresistantsivchallengesinrhesusmonkeys‏ ‎‡A Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys‏ ‎‡9 1‏
919 ‎‡a vaccineinductionofantibodiesagainstastructurallyheterogeneoussiteofimmunepressurewithinhiv1envelopeproteinvariableregions1and2‏ ‎‡A Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2‏ ‎‡9 1‏
919 ‎‡a vaccineinducedplasmaigaspecificforthec1regionofthehiv1envelopeblocksbindingandeffectorfunctionofigg‏ ‎‡A Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.‏ ‎‡9 1‏
919 ‎‡a vaccineinducedhiv1envelopegp120constantregion1specificantibodiesexposeacd4inducibleepitopeandblocktheinteractionofhiv1gp140withgalactosylceramide‏ ‎‡A Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide‏ ‎‡9 1‏
919 ‎‡a vaccineinducedenvv1v2igg3correlateswithlowerhiv1infectionriskanddeclinessoonaftervaccination‏ ‎‡A Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination‏ ‎‡9 1‏
919 ‎‡a v2directedvaccinelikeantibodiesfromhiv1infectionidentifyanadditionalk169bindinglightchainmotifwithbroadadccactivity‏ ‎‡A V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity‏ ‎‡9 1‏
919 ‎‡a transcriptionalandposttranscriptionalregulationofcytokinegeneexpressioninhiv1antigenspecificcd8+tcellsthatmediatevirusinhibition‏ ‎‡A Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition‏ ‎‡9 1‏
919 ‎‡a tolllikereceptor78tlr78andtlr9agonistscooperatetoenhancehiv1envelopeantibodyresponsesinrhesusmacaques‏ ‎‡A Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques‏ ‎‡9 1‏
919 ‎‡a tolllikereceptor78‏ ‎‡A Toll-like receptor 7/8‏ ‎‡9 1‏
919 ‎‡a tissuememorybcellrepertoireanalysisafteralvacaidsvaxbegp120immunizationofrhesusmacaques‏ ‎‡A Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques‏ ‎‡9 1‏
919 ‎‡a 3yeardurabilityofimmuneresponsesinducedbyhivdnaandhivmodifiedvacciniavirusankaraandeffectofalatehivmodifiedvacciniavirusankaraboostintanzanianvolunteers‏ ‎‡A Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers‏ ‎‡9 1‏
919 ‎‡a thinkingoutsidethegatesinglecellassessmentsinmultipledimensions‏ ‎‡A Thinking outside the gate: single-cell assessments in multiple dimensions‏ ‎‡9 1‏
919 ‎‡a humanantibodyresponsetothesurfaceofmycobacteriumtuberculosis‏ ‎‡A The human antibody response to the surface of Mycobacterium tuberculosis‏ ‎‡9 1‏
919 ‎‡a functionandaffinitymaturationofhiv1gp120specificmonoclonalantibodiesderivedfromcolostralbcells‏ ‎‡A The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells‏ ‎‡9 1‏
919 ‎‡a 1tcellresponsetotransmittedfounderviruscontributestothecontrolofacuteviremiainhiv1infection‏ ‎‡A The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection‏ ‎‡9 1‏
919 ‎‡a externalqualityassuranceoversightlaboratoryeqapolproficiencyprogramforifngammaenzymelinkedimmunospotifnγelispotassay‏ ‎‡A The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay‏ ‎‡9 1‏
919 ‎‡a externalqualityassuranceoversightlaboratory‏ ‎‡A The External Quality Assurance Oversight Laboratory‏ ‎‡9 1‏
919 ‎‡a centerforhivaidsvaccineimmunologychavimultisitequalityassuranceprogramforcryopreservedhumanperipheralbloodmononuclearcells‏ ‎‡A The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells‏ ‎‡9 1‏
919 ‎‡a centerforhivaidsvaccineimmunology‏ ‎‡A The Center for HIV/AIDS Vaccine Immunology‏ ‎‡9 1‏
919 ‎‡a teachingadvancedflowcytometryinafrica10yearsoflessonslearned‏ ‎‡A Teaching advanced flow cytometry in Africa: 10 years of lessons learned‏ ‎‡9 1‏
919 ‎‡a targetinghiv1envgp140tolox1elicitsimmuneresponsesinrhesusmacaques‏ ‎‡A Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques‏ ‎‡9 1‏
919 ‎‡a tcellassaysandmiatatheessentialminimumformaximumimpact‏ ‎‡A T Cell Assays and MIATA: The Essential Minimum for Maximum Impact‏ ‎‡9 1‏
919 ‎‡a surfaceexpressionpatternsofnegativeregulatorymoleculesidentifydeterminantsofvirusspecificcd8+tcellexhaustioninhivinfection‏ ‎‡A Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection‏ ‎‡9 1‏
919 ‎‡a superiorityinrhesusmacaquesoftargetinghiv1envgp140tocd40versuslox1incombinationwithreplicationcompetentnyvackcforinductionofenvspecificantibodyandtcellresponses‏ ‎‡A Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses‏ ‎‡9 1‏
919 ‎‡a strainspecificv3andcd4bindingsiteautologoushiv1neutralizingantibodiesselectneutralizationresistantviruses‏ ‎‡A Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses‏ ‎‡9 1‏
919 ‎‡a sivmac239mvavaccinewithandwithoutadnaprimesimilarpreventionofinfectionbyarepeateddosesivsme660challengedespitedifferentimmuneresponses‏ ‎‡A SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses‏ ‎‡9 1‏
919 ‎‡a safetypharmacokineticsandimmunologicalactivitiesofmultipleintravenousorsubcutaneousdosesofanantihivmonoclonalantibodyvrc01administeredtohivuninfectedadultsresultsofaphase1randomizedtrial‏ ‎‡A Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.‏ ‎‡9 1‏
919 ‎‡a safetyandimmunogenicityofcytotoxictlymphocytepolyepitopednaplasmidephiv1090vaccineinhealthyhumanimmunodeficiencyvirustype1hiv1uninfectedadults‏ ‎‡A Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults‏ ‎‡9 1‏
919 ‎‡a safetyandimmunogenicityofactlmultiepitopepeptidevaccineforhivwithorwithoutgmcsfinaphase1trial‏ ‎‡A Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial‏ ‎‡9 1‏
919 ‎‡a resultsofanelispotproficiencypanelconductedin11laboratoriesparticipatingininternationalhumanimmunodeficiencyvirustype1vaccinetrials‏ ‎‡A Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials‏ ‎‡9 1‏
919 ‎‡a responsetocommentoncd4+cd8+tcellsrepresentasignificantportionoftheantihivtcellresponsetoacutehivinfection‏ ‎‡A Response to Comment on "CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection" ‏ ‎‡9 1‏
919 ‎‡a replicationcompetentnyvackcyieldsimprovedimmunogenicitytohiv1antigensinrhesusmacaquescomparedtononreplicatingnyvac‏ ‎‡A Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenfunctionalprofileofhiv1specificcd8tcellsandepitopevariabilitywiththeselectionofescapemutantsinacutehiv1infection‏ ‎‡A Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection‏ ‎‡9 1‏
919 ‎‡a protectionaffordedbyanhivvaccinecandidateinmacaquesdependsonthedoseofsivmac251atchallengeexposure‏ ‎‡A Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure‏ ‎‡9 1‏
919 ‎‡a prolongedcd4+cellvirusloaddiscordanceduringtreatmentwithproteaseinhibitorbasedhighlyactiveantiretroviraltherapyimmuneresponseandviralcontrol‏ ‎‡A Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control‏ ‎‡9 1‏
919 ‎‡a progressinhiv1vaccinedevelopment‏ ‎‡A Progress in HIV-1 vaccine development.‏ ‎‡9 1‏
919 ‎‡a primingwithapotenthiv1dnavaccineframesthequalityofimmuneresponsespriortoapoxvirusandproteinboost‏ ‎‡A Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost‏ ‎‡9 1‏
919 ‎‡a preventionofinfectionbyagranulocytemacrophagecolonystimulatingfactorcoexpressingdnamodifiedvacciniaankarasimianimmunodeficiencyvirusvaccine‏ ‎‡A Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine‏ ‎‡9 1‏
919 ‎‡a potentialtostreamlineheterologousdnaprimeandnyvacproteinboosthivvaccineregimensinrhesusmacaquesbyemployingimprovedantigens‏ ‎‡A Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens‏ ‎‡9 1‏
919 ‎‡a potentfunctionalantibodyresponseselicitedbyhiv1dnaprimingandboostingwithheterologoushiv1recombinantmvainhealthytanzanianadults‏ ‎‡A Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults‏ ‎‡9 1‏
919 ‎‡a phenotypicandfunctionalprofileofhivinhibitorycd8tcellselicitedbynaturalinfectionandheterologousprimeboostvaccination‏ ‎‡A Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination‏ ‎‡9 1‏
919 ‎‡a phase2studyofanhiv1canarypoxvaccinevcp1452aloneandincombinationwithrgp120negativeresultsfailtotriggeraphase3correlatestrial‏ ‎‡A Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial‏ ‎‡9 1‏
919 ‎‡a performanceofserumsupplementedandserumfreemediainifngammaelispotassaysforhumantcells‏ ‎‡A Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells‏ ‎‡9 1‏
919 ‎‡a perforinandil2upregulationdefinequalitativedifferencesamonghighlyfunctionalvirusspecifichumancd8tcells‏ ‎‡A Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells‏ ‎‡9 1‏
919 ‎‡a pentavalenthiv1vaccineprotectsagainstsimianhumanimmunodeficiencyviruschallenge‏ ‎‡A Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge‏ ‎‡9 1‏
919 ‎‡a p1121inductionofpersistentmucosalhumoralandcellularresponsesfollowingimmunizationofmicewithhiv1envelopeproteinininulinderivedadjuvants‏ ‎‡A P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants‏ ‎‡9 1‏
919 ‎‡a optimizationofstorageandshipmentofcryopreservedperipheralbloodmononuclearcellsfromhivinfectedanduninfectedindividualsforelispotassays‏ ‎‡A Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays‏ ‎‡9 1‏
919 ‎‡a oligoclonalcd8lymphocytesfrompersonswithasymptomatichumanimmunodeficiencyvirushivtype1infectioninhibithiv1replication‏ ‎‡A Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication.‏ ‎‡9 1‏
919 ‎‡a neutralizingandotherantiviralantibodiesinhiv1infectionandvaccination‏ ‎‡A Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination‏ ‎‡9 1‏
919 ‎‡a neutralizationtakesprecedenceoveriggorigaisotyperelatedfunctionsinmucosalhiv1antibodymediatedprotection‏ ‎‡A Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection‏ ‎‡9 1‏
919 ‎‡a naivetcellsaremaintainedintheperipheryduringthefirst3monthsofacutehiv1infectionimplicationsforanalysisofthymusfunction‏ ‎‡A Naïve T Cells Are Maintained in the Periphery During the First3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function‏ ‎‡9 1‏
919 ‎‡a mucosalimmunizationoflactatingfemalerhesusmonkeyswithatransmittedfounderhiv1envelopeinducesstrongenvspecificigaantibodyresponsesinbreastmilk‏ ‎‡A Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk‏ ‎‡9 1‏
919 ‎‡a measurementofcytokinereleaseatthesinglecelllevelusingtheelispotassay‏ ‎‡A Measurement of cytokine release at the single cell level using the ELISPOT assay‏ ‎‡9 1‏
919 ‎‡a maternalhiv1envelopespecificantibodyresponsesandreducedriskofperinataltransmission‏ ‎‡A Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission‏ ‎‡9 1‏
919 ‎‡a maternalhiv1envvaccinationforsystemicandbreastmilkimmunitytopreventoralshivacquisitionininfantmacaques‏ ‎‡A Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques.‏ ‎‡9 1‏
919 ‎‡a massivecd8tcellresponsetoprimaryhivinfectioninthesettingofsevereclinicalpresentation‏ ‎‡A Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation‏ ‎‡9 1‏
919 ‎‡a lymphnodetcellresponsespredicttheefficacyofliveattenuatedsivvaccines‏ ‎‡A Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines‏ ‎‡9 1‏
919 ‎‡a longitudinalassessmentofimmuneresponseandviralcharacteristicsinhivinfectedpatientswithprolongedcd4+viralloaddiscordance‏ ‎‡A Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4+/Viral Load Discordance‏ ‎‡9 1‏
919 ‎‡a lipidnanoparticleencapsulatednucleosidemodifiedmrnavaccineselicitpolyfunctionalhiv1antibodiescomparabletoproteinsinnonhumanprimates‏ ‎‡A Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates‏ ‎‡9 1‏
919 ‎‡a leukopakpbmcsampleprocessingforpreparingqualitycontrolmaterialtosupportproficiencytestingprograms‏ ‎‡A Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs‏ ‎‡9 1‏
919 ‎‡a lackofinfectioninhivexposedindividualsisassociatedwithastrongcd8+cellnoncytotoxicantihivresponse‏ ‎‡A Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response‏ ‎‡9 1‏
919 ‎‡a lackofinfectioninhivexposedindividualsisassociatedwithastrongcd8‏ ‎‡A Lack of infection in HIV-exposed individuals is associated with a strong CD8‏ ‎‡9 1‏
919 ‎‡a isolationofhiv1neutralizingmucosalmonoclonalantibodiesfromhumancolostrum‏ ‎‡A Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum‏ ‎‡9 1‏
919 ‎‡a intradermalhiv1dnaimmunizationusingneedlefreezetajetsuptmsupinjectionfollowedbyhivmodifiedvacciniavirusankaravaccinationissafeandimmunogenicinmozambicanyoungadultsaphase1randomizedcontrolledtrial‏ ‎‡A Intradermal HIV-1 DNA immunization using needle-free Zetajet<sup>TM</sup> injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.‏ ‎‡9 1‏
919 ‎‡a interactionwithcellularcd4exposeshiv1envelopeepitopestargetedbyantibodydependentcellmediatedcytotoxicity‏ ‎‡A Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity‏ ‎‡9 1‏
919 ‎‡a innateimmunesignaturestoapartiallyefficacioushivvaccinepredictcorrelatesofhiv1infectionrisk‏ ‎‡A Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk‏ ‎‡9 1‏
919 ‎‡a initialhiv1antigenspecificcd8+tcellsinacutehiv1infectioninhibittransmittedfoundervirusreplication‏ ‎‡A Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication‏ ‎‡9 1‏
919 ‎‡a infectiousvirioncapturebyhiv1gp120specificiggfromrv144vaccinees‏ ‎‡A Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees‏ ‎‡9 1‏
919 ‎‡a infanthivtype1gp120vaccinationelicitsrobustanddurableantiv1v2immunoglobulingresponsesandonlyrareenvelopespecificimmunoglobulinaresponses‏ ‎‡A Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses‏ ‎‡9 1‏
919 ‎‡a inductionofplasmatrailtnfr2fasligandandplasmamicroparticlesafterhumanimmunodeficiencyvirustype1hiv1transmissionimplicationsforhiv1vaccinedesign‏ ‎‡A Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design‏ ‎‡9 1‏
919 ‎‡a inductionofheterologoustier2hiv1neutralizingandcrossreactivev1v2specificantibodiesinrabbitsbyprimeboostimmunization‏ ‎‡A Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization‏ ‎‡9 1‏
919 ‎‡a increaseddurablebcellandadccresponsesassociatedwiththelperresponsestohiv1envelopeinmacaquesvaccinatedwithgp140occludedatthecd4receptorbindingsite‏ ‎‡A Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site‏ ‎‡9 1‏
919 ‎‡a inclusionofacrf01aehivenvelopeproteinboostwithadnamvaprimeboostvaccineimpactonhumoralandcellularimmunogenicityandviralloadreductionaftershivechallenge‏ ‎‡A Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge‏ ‎‡9 1‏
919 ‎‡a impactofimmuneescapemutationsonhiv1fitnessinthecontextofthecognatetransmittedfoundergenome‏ ‎‡A Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome‏ ‎‡9 1‏
919 ‎‡a immunologicalandvirologicalmechanismsofvaccinemediatedprotectionagainstsivandhiv‏ ‎‡A Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.‏ ‎‡9 1‏
919 ‎‡a immunologicandvirologicmechanismsforpartialprotectionfromintravenouschallengebyanintegrationdefectivesivvaccine‏ ‎‡A Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine‏ ‎‡9 1‏
919 ‎‡a immunogenicityofanovelcladebhiv1vaccinecombinationresultsofphase1randomizedplacebocontrolledtrialofanhiv1gmcsfexpressingdnaprimewithamodifiedvacciniaankaravaccineboostinhealthyhiv1uninfectedadults‏ ‎‡A Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults‏ ‎‡9 1‏
919 ‎‡a immunodominanceandcrossreactivityofb5703restrictedcd8tlymphocytesfromhivtype1subtype100infectedethiopians‏ ‎‡A Immunodominance and Cross-Reactivity of B5703-Restricted CD8 T Lymphocytes from HIV Type 1 Subtype C-Infected Ethiopians‏ ‎‡9 1‏
919 ‎‡a immunizationwithansivbasedidlvexpressinghiv1env1086clade100elicitsdurablehumoralandcellularresponsesinrhesusmacaques‏ ‎‡A Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques‏ ‎‡9 1‏
919 ‎‡a immunecorrelatesofthethairv144hivvaccineregimeninsouthafrica‏ ‎‡A Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa‏ ‎‡9 1‏
919 ‎‡a immunecorrelatesanalysisofanhiv1vaccineefficacytrial‏ ‎‡A Immune-correlates analysis of an HIV-1 vaccine efficacy trial‏ ‎‡9 1‏
919 ‎‡a 7enhancementofantigendrivenactivationexpansionofhiv1specificcytotoxictlymphocyteprecursorsctlp‏ ‎‡A IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).‏ ‎‡9 1‏
919 ‎‡a identificationofeffectivesubdominantantihiv1cd8+tcellswithinentirepostinfectionandpostvaccinationimmuneresponses‏ ‎‡A Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses‏ ‎‡9 1‏
919 ‎‡a humoralandinnateantiviralimmunityastoolstoclearpersistenthivinfection‏ ‎‡A Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection‏ ‎‡9 1‏
919 ‎‡a humannonneutralizinghiv1envelopemonoclonalantibodieslimitthenumberoffoundervirusesduringshivmucosalinfectioninrhesusmacaques‏ ‎‡A Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques‏ ‎‡9 1‏
919 ‎‡a hlaclass2genesmodulatevaccineinducedantibodyresponsestoaffecthiv1acquisition‏ ‎‡A HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition‏ ‎‡9 1‏
919 ‎‡a hlaaandballeleexpressionandabilitytodevelopantigagcrosscladeresponsesinsubtype100hiv1infectedethiopians‏ ‎‡A HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians‏ ‎‡9 1‏
919 ‎‡a hivspecificfunctionalantibodyresponsesinbreastmilkmirrorthoseinplasmaandareprimarilymediatedbyiggantibodies‏ ‎‡A HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies‏ ‎‡9 1‏
919 ‎‡a hivevolutioninearlyinfectionselectionpressurespatternsofinsertionanddeletionandtheimpactofapobec‏ ‎‡A HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC‏ ‎‡9 1‏
919 ‎‡a hivantibodiesfortreatmentofhivinfection‏ ‎‡A HIV antibodies for treatment of HIV infection‏ ‎‡9 1‏
919 ‎‡a hivaidsvaccinecandidatesbasedonreplicationcompetentrecombinantpoxvirusnyvac100kcexpressingtrimericgp140andgagderivedviruslikeparticlesorlackingtheviralmoleculeb19thatinhibitstype1interferonactivaterelevanthiv1speci‏ ‎‡A HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci‏ ‎‡9 1‏
919 ‎‡a hiv1vaccinesdiversionofhiv1vaccineinducedimmunitybygp41microbiotacrossreactiveantibodies‏ ‎‡A HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies‏ ‎‡9 1‏
919 ‎‡a hiv1vaccineinducedc1andv2envspecificantibodiessynergizeforincreasedantiviralactivities‏ ‎‡A HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities‏ ‎‡9 1‏
919 ‎‡a hiv1specificigamonoclonalantibodiesfromanhiv1vaccineemediategalcerblockingandphagocytosis‏ ‎‡A HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis‏ ‎‡9 1‏
919 ‎‡a hiv1gp120vaccineinducesaffinitymaturationinbothnewandpersistentantibodyclonallineages‏ ‎‡A HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages‏ ‎‡9 1‏
919 ‎‡a hiv1gp120andmodifiedvacciniavirusankaramvagp140boostimmunogensincreaseimmunogenicityofadnamvahiv1vaccine‏ ‎‡A HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine‏ ‎‡9 1‏
919 ‎‡a hiv1consensusenvelopeinducedbroadlybindingantibodies‏ ‎‡A HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies‏ ‎‡9 1‏
919 ‎‡a highthroughputquantitativeanalysisofhiv1andsivspecificadccmediatingantibodyresponses‏ ‎‡A High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses‏ ‎‡9 1‏
919 ‎‡a highdoserecombinantcanarypoxvaccineexpressinghiv1proteininseronegativehumansubjects‏ ‎‡A High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects‏ ‎‡9 1‏
919 ‎‡a highantibodydependentcellularcytotoxicityresponsesarecorrelatedwithstrongcd8tcellviralsuppressiveactivitybutnotwithb57statusinhiv1elitecontrollers‏ ‎‡A High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers‏ ‎‡9 1‏
919 ‎‡a heterogeneousneutralizingantibodyandantibodydependentcellcytotoxicityresponsesinhiv1elitecontrollers‏ ‎‡A Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers‏ ‎‡9 1‏
919 ‎‡a headtoheadcomparisonofpoxvirusnyvacandalvacvectorsexpressingidenticalhiv1clade100immunogensinprimeboostcombinationwithenvproteininnonhumanprimates‏ ‎‡A Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates‏ ‎‡9 1‏
919 ‎‡a gnidimacrinapotentantihivditerpenecaneliminatelatenthiv1exvivobyactivationofproteinkinase100β‏ ‎‡A Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.‏ ‎‡9 1‏
919 ‎‡a fixeddosecombinationemtricitabinetenofovirefavirenzinitiatedduringacutehivinfection96weekefficacyanddurability‏ ‎‡A Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.‏ ‎‡9 1‏
919 ‎‡a fitnesscostsanddiversityofthecytotoxictlymphocytectlresponsedeterminetherateofctlescapeduringacuteandchronicphasesofhivinfection‏ ‎‡A Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection‏ ‎‡9 1‏
919 ‎‡a fcgr2cpolymorphismsassociatewithhiv1vaccineprotectioninrv144trial‏ ‎‡A FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial‏ ‎‡9 1‏
919 ‎‡a excellentsafetyandtolerabilityofthehumanimmunodeficiencyvirustype1pga2js2plasmiddnaprimingvectorvaccineinhivtype1uninfectedadults‏ ‎‡A Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults‏ ‎‡9 1‏
919 ‎‡a establishmentandmaintenanceofapbmcrepositoryforfunctionalcellularstudiesinsupportofclinicalvaccinetrials‏ ‎‡A Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials‏ ‎‡9 1‏
919 ‎‡a erratumcorrigendumadjuvantdependentinnateandadaptiveimmunesignaturesofriskofsivmac251acquisition‏ ‎‡A Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition‏ ‎‡9 1‏
919 ‎‡a epitopespecificityofhumanimmunodeficiencyvirus1antibodydependentcellularcytotoxicityresponses‏ ‎‡A Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses‏ ‎‡9 1‏
919 ‎‡a envelopespecificbcellpopulationsinafricangreenmonkeyschronicallyinfectedwithsimianimmunodeficiencyvirus‏ ‎‡A Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus‏ ‎‡9 1‏
919 ‎‡a envelopespecificantibodiesandantibodyderivedmoleculesfortreatingandcuringhivinfection‏ ‎‡A Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection‏ ‎‡9 1‏
919 ‎‡a endpointassaysinhiv1vaccinetrialsfunctioninginagoodlaboratorypracticesenvironment‏ ‎‡A Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment‏ ‎‡9 1‏
919 ‎‡a endingaidsasapublichealththreatby2030scientificdevelopmentsfromthe2016interestconferenceinyaoundecameroon‏ ‎‡A Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.‏ ‎‡9 1‏
919 ‎‡a efficacyofnnrtibasedantiretroviraltherapyinitiatedduringacutehivinfection‏ ‎‡A Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection‏ ‎‡9 1‏
919 ‎‡a effectofhighlyactiveantiretroviraltherapyandthymictransplantationonimmunoreconstitutioninhivinfection‏ ‎‡A Effect of Highly Active Antiretroviral Therapy and Thymic Transplantation on Immunoreconstitution in HIV Infection‏ ‎‡9 1‏
919 ‎‡a durablehiv1antibodyandtcellresponseselicitedbyanadjuvantedmultiproteinrecombinantvaccineinuninfectedhumanvolunteers‏ ‎‡A Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers‏ ‎‡9 1‏
919 ‎‡a dualaffinityretargetingproteinsdirecttcellmediatedcytolysisoflatentlyhivinfectedcells‏ ‎‡A Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells‏ ‎‡9 1‏
919 ‎‡a dnamvaproteinvaccinationofrhesusmacaquesinduceshivspecificimmunityinmucosalassociatedlymphnodesandfunctionalantibodies‏ ‎‡A DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies‏ ‎‡9 1‏
919 ‎‡a diversityofantiviraliggeffectoractivitiesobservedinhivinfectedandvaccinatedsubjects‏ ‎‡A Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects‏ ‎‡9 1‏
919 ‎‡a distinctkineticsofgagspecificcd4+andcd8+tcellresponsesduringacutehiv1infection‏ ‎‡A Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection‏ ‎‡9 1‏
919 ‎‡a discriminatingbetweenlatentandactivetuberculosiswithmultiplebiomarkerresponses‏ ‎‡A Discriminating between latent and active tuberculosis with multiple biomarker responses.‏ ‎‡9 1‏
919 ‎‡a crosslinkingofacd4mimeticminiproteinwithhiv1envgp140alterskineticsandspecificitiesofantibodyresponsesagainsthiv1envinmacaques‏ ‎‡A Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques‏ ‎‡9 1‏
919 ‎‡a crosssectionaldetectionofacutehivinfectiontimingoftransmissioninflammationandantiretroviraltherapy‏ ‎‡A Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a correctionforkibleretalreplicationcompetentnyvackcyieldsimprovedimmunogenicitytohiv1antigensinrhesusmacaquescomparedtononreplicatingnyvac‏ ‎‡A Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC" ‏ ‎‡9 1‏
919 ‎‡a cooperationofbcelllineagesininductionofhiv1broadlyneutralizingantibodies‏ ‎‡A Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies‏ ‎‡9 1‏
919 ‎‡a controlofheterologoussimianimmunodeficiencyvirussivinfectionbydnaandproteincoimmunizationregimenscombinedwithdifferenttolllikereceptor4basedadjuvantsinmacaques‏ ‎‡A Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques‏ ‎‡9 1‏
919 ‎‡a comparisonofsystemicandmucosalimmunizationwithhelperdependentadenovirusesforvaccinationagainstmucosalchallengewithshiv‏ ‎‡A Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.‏ ‎‡9 1‏
919 ‎‡a comparativeimmunogenicityofhiv1gp140vaccinedeliveredbyparenteralandmucosalroutesinfemalevolunteersmucovac2arandomized2centrestudy‏ ‎‡A Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study‏ ‎‡9 1‏
919 ‎‡a combinedhiv1envelopesystemicandmucosalimmunizationoflactatingrhesusmonkeysinducesarobustimmunoglobulinaisotypebcellresponseinbreastmilk‏ ‎‡A Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk‏ ‎‡9 1‏
919 ‎‡a cladebbasedhiv1vaccineselicitcrosscladecytotoxictlymphocytereactivitiesinuninfectedvolunteers‏ ‎‡A Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers‏ ‎‡9 1‏
919 ‎‡a characterizationofhiv1nucleosidemodifiedmrnavaccinesinrabbitsandrhesusmacaques‏ ‎‡A Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques‏ ‎‡9 1‏
919 ‎‡a characterizationoffunctionalandphenotypicchangesinantigagvaccineinducedtcellresponsesandtheirroleinprotectionafterhiv1infection‏ ‎‡A Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection‏ ‎‡9 1‏
919 ‎‡a cd8+tcellmediatedsuppressiveactivityinhibitshiv1aftervirusentrywithkineticsindicatingeffectsonvirusgeneexpression‏ ‎‡A CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.‏ ‎‡9 1‏
919 ‎‡a cd8ctlresponsesinvaccinesemergingpatternsofhlarestrictionandepitoperecognition‏ ‎‡A CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition‏ ‎‡9 1‏
919 ‎‡a cd4+cd8+tcellsrepresentasignificantportionoftheantihivtcellresponsetoacutehivinfection‏ ‎‡A CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection‏ ‎‡9 1‏
919 ‎‡a boostingwithsubtype100cn54rgp140proteinadjuvantedwithglucopyranosyllipidadjuvantafterprimingwithhivdnaandhivmvaissafeandenhancesimmuneresponsesaphase1trial‏ ‎‡A Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial‏ ‎‡9 1‏
919 ‎‡a boostingofhivenvelopecd4bindingsiteantibodieswithlongvariableheavy3complementaritydeterminingregionintherandomizeddoubleblindrv305hiv1vaccinetrial‏ ‎‡A Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.‏ ‎‡9 1‏
919 ‎‡a boostingofalvacsivvaccineprimedmacaqueswiththecd4sivgp120fusionproteinelicitsantibodiestov2associatedwithadecreasedriskofsivmac251acquisition‏ ‎‡A Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition‏ ‎‡9 1‏
919 ‎‡a beyondviralneutralization‏ ‎‡A Beyond Viral Neutralization‏ ‎‡9 1‏
919 ‎‡a automatingproceduresforprocessingcryopreservationstorageandmanipulationofhumanperipheralbloodmononuclearcells‏ ‎‡A Automating Procedures for Processing, Cryopreservation, Storage, and Manipulation of Human Peripheral Blood Mononuclear Cells‏ ‎‡9 1‏
919 ‎‡a associationofhiv1envelopespecificbreastmilkigaresponseswithreducedriskofpostnatalmothertochildtransmissionofhiv1‏ ‎‡A Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1‏ ‎‡9 1‏
919 ‎‡a applicationofareascalinganalysistoidentifynaturalkillercellandmonocyteinvolvementinthegrantoxiluxantibodydependentcellmediatedcytotoxicityassay‏ ‎‡A Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.‏ ‎‡9 1‏
919 ‎‡a antiretroviraltherapyinitiatedduringacutehivinfectionfailstopreventpersistenttcellactivation‏ ‎‡A Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation‏ ‎‡9 1‏
919 ‎‡a antigenspecifictcellmediatedimmunityafterhiv1infectionimplicationsforvaccinecontrolofhivdevelopment‏ ‎‡A Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development‏ ‎‡9 1‏
919 ‎‡a antibodytothegp120v1v2loopsandcd4+andcd8+tcellresponsesinprotectionfromsivmac251vaginalacquisitionandpersistentviremia‏ ‎‡A Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia‏ ‎‡9 1‏
919 ‎‡a antibodydependentcellularcytotoxicitymediatingantibodiesfromanhiv1vaccineefficacytrialtargetmultipleepitopesandpreferentiallyusethevh1genefamily‏ ‎‡A Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family‏ ‎‡9 1‏
919 ‎‡a antibodieswithhighaviditytothegp120envelopeproteininprotectionfromsimianimmunodeficiencyvirussivmac251acquisitioninanimmunizationregimenthatmimicstherv144thaitrial‏ ‎‡A Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial‏ ‎‡9 1‏
919 ‎‡a hivenvelopegp120fcfusionproteinelicitseffectorantibodyresponsesinrhesusmacaques‏ ‎‡A An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques‏ ‎‡9 1‏
919 ‎‡a hiv1gp120envelopehumanmonoclonalantibodythatrecognizesac1conformationalepitopemediatespotentantibodydependentcellularcytotoxicityadccactivityanddefinesacommonadccepitopeinhumanhiv1serum‏ ‎‡A An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum‏ ‎‡9 1‏
919 ‎‡a enhancedsyntheticmulticladednaprimeinducesimprovedcrosscladereactivefunctionalantibodieswhencombinedwithanadjuvantedproteinboostinnonhumanprimates‏ ‎‡A An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.‏ ‎‡9 1‏
919 ‎‡a aggregatecomplexesofhiv1inducedbymultimericantibodies‏ ‎‡A Aggregate complexes of HIV-1 induced by multimeric antibodies‏ ‎‡9 1‏
919 ‎‡a adjuvantedhiv1vaccinepromotesantibodydependentphagocyticresponsesandprotectsagainstheterologousshivchallenge‏ ‎‡A Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge‏ ‎‡9 1‏
919 ‎‡a adjuvantdependentmucosalv2responsesandrasactivationinvaccineinducedprotectionfromsivmac251acquisition‏ ‎‡A Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.‏ ‎‡9 1‏
919 ‎‡a adjuvantdependentinnateandadaptiveimmunesignaturesofriskofsivmac251acquisition‏ ‎‡A Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition‏ ‎‡9 1‏
919 ‎‡a acutehivinfectiontheimpactofantiretroviraltreatmentoncellularimmuneresponses‏ ‎‡A Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses‏ ‎‡9 1‏
919 ‎‡a acutehiv1infectioninthesoutheasternunitedstatesacohortstudy‏ ‎‡A Acute HIV-1 infection in the Southeastern United States: a cohort study‏ ‎‡9 1‏
919 ‎‡a absenceofimmunodominantantigagp17sl9responsesamonggagctlpositivehivuninfectedvaccinerecipientsexpressingthehlaa0201allele‏ ‎‡A Absence of Immunodominant Anti-Gag p17 (SL9) Responses among Gag CTL-Positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele‏ ‎‡9 1‏
919 ‎‡a trimerichiv1envelopegp120immunogeninducespotentandbroadantiv1v2loopantibodiesagainsthiv1inrabbitsandrhesusmacaques‏ ‎‡A A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques‏ ‎‡9 1‏
919 ‎‡a stronglyselectedmutationinthehiv1genomeisindependentoftcellresponsesandneutralizingantibodies‏ ‎‡A A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.‏ ‎‡9 1‏
919 ‎‡a phase1trialofpreventivehivvaccinationwithheterologouspoxviralvectorscontainingmatchinghiv1insertsinhealthyhivuninfectedsubjects‏ ‎‡A A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects‏ ‎‡9 1‏
919 ‎‡a panelofmhcclass1restrictedviralpeptidesforuseasaqualitycontrolforvaccinetrialelispotassays‏ ‎‡A A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays‏ ‎‡9 1‏
919 ‎‡a highlyconservedresidueofthehiv1gp120innerdomainisimportantforantibodydependentcellularcytotoxicityresponsesmediatedbyanticlusteraantibodies‏ ‎‡A A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies‏ ‎‡9 1‏
919 ‎‡a clusterofhivtype1subtype100sequencesfromethiopiaobservedinfullgenomeanalysisisnotsustainedinsubgenomicregions‏ ‎‡A A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions‏ ‎‡9 1‏
919 ‎‡a lossofdnam1contributestocd8+tcellexhaustioninchronichiv1infection‏ ‎‡A Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2016‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 NTA|096768142‏
996 ‎‡2 RERO|A003239272‏
996 ‎‡2 NUKAT|n 2008107763‏
996 ‎‡2 ISNI|0000000432629356‏
996 ‎‡2 ISNI|0000000387806455‏
996 ‎‡2 BNCHL|10000000000000000227947‏
996 ‎‡2 BNE|XX1653054‏
996 ‎‡2 ISNI|0000000022299673‏
996 ‎‡2 J9U|987007281669705171‏
996 ‎‡2 BIBSYS|98033524‏
996 ‎‡2 BIBSYS|10009779‏
996 ‎‡2 BNC|981058527946906706‏
996 ‎‡2 LC|no2010046219‏
996 ‎‡2 LC|n 83068899‏
996 ‎‡2 SUDOC|123234026‏
996 ‎‡2 BAV|495_80906‏
996 ‎‡2 NTA|114984697‏
996 ‎‡2 BAV|495_80903‏
996 ‎‡2 ISNI|0000000061265724‏
996 ‎‡2 BAV|495_173045‏
996 ‎‡2 DNB|1063142989‏
996 ‎‡2 PTBNP|159234‏
996 ‎‡2 DNB|1252395248‏
996 ‎‡2 RERO|A003239296‏
996 ‎‡2 NTA|114984948‏
996 ‎‡2 ISNI|0000000061297523‏
996 ‎‡2 PLWABN|9813705720305606‏
996 ‎‡2 RERO|A003239299‏
996 ‎‡2 LC|no2011003758‏
996 ‎‡2 SUDOC|083558632‏
996 ‎‡2 LC|n 2002046485‏
996 ‎‡2 LC|n 95801276‏
996 ‎‡2 PLWABN|9810543977805606‏
996 ‎‡2 NKC|jn20040109028‏
996 ‎‡2 BNF|14409364‏
996 ‎‡2 DNB|171605756‏
996 ‎‡2 BNF|14097418‏
996 ‎‡2 SUDOC|16629473X‏
996 ‎‡2 LC|no2008156967‏
996 ‎‡2 DNB|127047956‏
996 ‎‡2 CAOONL|ncf10456087‏
996 ‎‡2 NSK|000240851‏
996 ‎‡2 NKC|xx0090605‏
996 ‎‡2 LC|nr2004032928‏
996 ‎‡2 J9U|987007448943005171‏
996 ‎‡2 BAV|495_293529‏
996 ‎‡2 SUDOC|177126523‏
996 ‎‡2 ICCU|CUBV093731‏
996 ‎‡2 ISNI|0000000110262168‏
996 ‎‡2 ISNI|0000000108650348‏
996 ‎‡2 LC|n 91028360‏
996 ‎‡2 SUDOC|243268599‏
996 ‎‡2 CAOONL|ncf11542986‏
996 ‎‡2 BNF|16723126‏
996 ‎‡2 SUDOC|081296045‏
996 ‎‡2 SUDOC|088450740‏
996 ‎‡2 ISNI|0000000376453324‏
996 ‎‡2 ISNI|0000000053245248‏
996 ‎‡2 BAV|495_173050‏
996 ‎‡2 DNB|132831392‏
996 ‎‡2 NUKAT|n 2019069969‏
996 ‎‡2 SZ|1252395248‏
996 ‎‡2 ICCU|UBOV119922‏
996 ‎‡2 NSK|000264813‏
996 ‎‡2 RERO|A023293504‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏